Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review.

作者: Eleftherios Pelechas , Alexandra Papoudou-Bai , Paraskevi V Voulgari , Alexandros A Drosos , None

DOI: 10.1007/S00296-018-4212-0

关键词: PrednisoneMedicineDermatologyRheumatoid arthritisTocilizumabHydroxychloroquineSkin biopsyGranuloma annulareRheumatologyInfliximabInternal medicine

摘要: Granuloma annulare (GA) is the most common non-infectious disease. Despite fact that it a benign disease, can be associated with variety of disorders and certain drugs including biological disease-modifying anti-rheumatic (bDMARDs). A 50-year-old man history rheumatoid arthritis refractory to methotrexate, hydroxychloroquine infliximab was treated tocilizumab (TCZ), an interleukin-6 receptor antagonist, 162 mg subcutaneously every week. The patient responded very well TCZ treatment decrease acute phase reactants reduction disease activity score for 28-joints count. However, 3 months later he developed erythematous polycyclic eruptions affecting lower extremities consistent diagnosis GA which confirmed by skin biopsy. has been discontinued prednisone presenting complete resolution manifestations after 4 weeks. This first case development during treatment. Thus, we review literature discuss relevant cases in patients bDMARDs. When dealing these agents, all physicians should aware possible adverse events potential such complications.

参考文章(20)
Voulgari Pv, Kaltsonoudis Es, Markatseli Te, Drosos Aa, Zioga A, Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab Clinical and Experimental Rheumatology. ,vol. 27, pp. 996- 998 ,(2009)
M. Viguier, P. Richette, H. Bachelez, D. Wendling, F. Aubin, Manifestations cutanées paradoxales des anti-TNF-alpha Annales De Dermatologie Et De Venereologie. ,vol. 137, pp. 64- 71 ,(2010) , 10.1016/J.ANNDER.2009.10.003
Evripidis Kaltsonoudis, Anastasia K Zikou, Paraskevi V Voulgari, Spyridon Konitsiotis, Maria I Argyropoulou, Alexandros A Drosos, None, Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study Arthritis Research & Therapy. ,vol. 16, pp. 1- 7 ,(2014) , 10.1186/AR4582
Victor Manuel Martinez-Taboada, Lorena Alvarez, Maria RuizSoto, Maria Jose Marin-Vidalled, Marcos Lopez-Hoyos, Giant cell arteritis and polymyalgia rheumatica: Role of cytokines in the pathogenesis and implications for treatment Cytokine. ,vol. 44, pp. 207- 220 ,(2008) , 10.1016/J.CYTO.2008.09.004
S.A. Devos, N. van den Bossche, M. De Vos, J.M. Naeyaert, Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy Dermatology. ,vol. 206, pp. 388- 390 ,(2003) , 10.1159/000069965
SibaP Raychaudhuri, Mondhipa Ratnarathorn, Stanley Naguwa, Disseminated granuloma annulare: a cutaneous adverse effect of anti-tnf agents. Indian Journal of Dermatology. ,vol. 56, pp. 752- 754 ,(2011) , 10.4103/0019-5154.91847
Maxime Samson, Sylvain Audia, Jennifer Fraszczak, Malika Trad, Paul Ornetti, Daniela Lakomy, Marion Ciudad, Vanessa Leguy, Sabine Berthier, Julien Vinit, Patrick Manckoundia, Jean-Francis Maillefert, Jean-François Besancenot, Serge Aho-Glele, Nils Olivier Olsson, Bernard Lorcerie, Loïc Guillevin, Luc Mouthon, Philippe Saas, Andrew Bateman, Laurent Martin, Nona Janikashvili, Nicolas Larmonier, Bernard Bonnotte, Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis & Rheumatism. ,vol. 64, pp. 3788- 3798 ,(2012) , 10.1002/ART.34647
P. P. Sfikakis, A. Iliopoulos, A. Elezoglou, C. Kittas, A. Stratigos, Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis & Rheumatism. ,vol. 52, pp. 2513- 2518 ,(2005) , 10.1002/ART.21233
Jonathan S. Alexander, Parwathi “Uma” Paniker, A ring-shaped eruption. The American Journal of Medicine. ,vol. 119, pp. 125- 127 ,(2006) , 10.1016/J.AMJMED.2005.12.002
Armen Yuri Gasparyan, Lilit Ayvazyan, Heather Blackmore, George D. Kitas, Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors Rheumatology International. ,vol. 31, pp. 1409- 1417 ,(2011) , 10.1007/S00296-011-1999-3